- Home
- LB vs ADPT Comparison
LB vs ADPT Comparison
Compare LB & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LB
- ADPT
- Stock Information
- Founded
- LB 1992
- ADPT 2009
- Country
- LB United States
- ADPT United States
- Employees
- LB N/A
- ADPT N/A
- Industry
- LB
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LB
- ADPT Health Care
- Exchange
- LB NYSE
- ADPT Nasdaq
- Market Cap
- LB 1.1B
- ADPT 929.8M
- IPO Year
- LB 2024
- ADPT 2019
- Fundamental
- Price
- LB $57.02
- ADPT $5.94
- Analyst Decision
- LB Buy
- ADPT Buy
- Analyst Count
- LB 8
- ADPT 4
- Target Price
- LB $40.63
- ADPT $6.50
- AVG Volume (30 Days)
- LB 603.7K
- ADPT 1.4M
- Earning Date
- LB 11-06-2024
- ADPT 02-12-2025
- Dividend Yield
- LB 0.17%
- ADPT N/A
- EPS Growth
- LB N/A
- ADPT N/A
- EPS
- LB 0.30
- ADPT N/A
- Revenue
- LB $90,912,000.00
- ADPT $177,282,000.00
- Revenue This Year
- LB $57.77
- ADPT $6.48
- Revenue Next Year
- LB $44.23
- ADPT $18.84
- P/E Ratio
- LB $193.83
- ADPT N/A
- Revenue Growth
- LB 26.93
- ADPT N/A
- 52 Week Low
- LB $18.75
- ADPT $2.28
- 52 Week High
- LB $80.82
- ADPT $7.07
- Technical
- Relative Strength Index (RSI)
- LB N/A
- ADPT 61.49
- Support Level
- LB N/A
- ADPT $5.98
- Resistance Level
- LB N/A
- ADPT $6.93
- Average True Range (ATR)
- LB 0.00
- ADPT 0.45
- MACD
- LB 0.00
- ADPT 0.03
- Stochastic Oscillator
- LB 0.00
- ADPT 75.53
About LB LANDBRIDGE COMPANY LLC
LandBridge Co LLC is engaged in managing land and resources to support and promote oil and natural gas development. It generate revenue streams from the use of its surface acreage, the sale of resources from land and oil and gas royalties.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).